<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002762" GROUP_ID="SYMPT" ID="300999122013550210" MERGED_FROM="" MODIFIED="2010-07-04 14:28:55 +0200" MODIFIED_BY="Caroline Struthers" REVIEW_NO="20" REVMAN_SUB_VERSION="5.0.13" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2010-07-04 14:28:55 +0200" MODIFIED_BY="Caroline Struthers">
<TITLE MODIFIED="2008-05-28 15:12:30 +0100" MODIFIED_BY="Sheena Derry">Single dose oral piroxicam for acute postoperative pain</TITLE>
<CONTACT MODIFIED="2010-07-04 14:28:55 +0200" MODIFIED_BY="Caroline Struthers"><PERSON ID="A54BF87E82E26AA201B8424EDA13C250" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Maura</FIRST_NAME><LAST_NAME>Moore</LAST_NAME><EMAIL_1>maura.moore@pru.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Pain Research and Nuffield Department of Anaesthetics</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>West Wing (Level 6)</ADDRESS_1><ADDRESS_2>John Radcliffe Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 234538</PHONE_1><FAX_1>+44 1865 234539</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-07-04 14:28:55 +0200" MODIFIED_BY="Caroline Struthers"><PERSON ID="7899" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>R Andrew</FIRST_NAME><LAST_NAME>Moore</LAST_NAME><SUFFIX>DSc</SUFFIX><POSITION>Research Director</POSITION><EMAIL_1>andrew.moore@pru.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Pain Research and Nuffield Department of Anaesthetics</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>West Wing (Level 6)</ADDRESS_1><ADDRESS_2>John Radcliffe Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 231512</PHONE_1><PHONE_2>+44 1865 234537</PHONE_2><FAX_1>+44 1865 334539</FAX_1></ADDRESS></PERSON><PERSON ID="4D32DC6982E26AA20145240A91884D05" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jayne</FIRST_NAME><LAST_NAME>Edwards</LAST_NAME><ADDRESS><DEPARTMENT>Training Team</DEPARTMENT><ORGANISATION>UK Cochrane Centre</ORGANISATION><ADDRESS_1>National Institute for Health Research</ADDRESS_1><ADDRESS_2>Summertown Pavilion, Middle Way</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 7LG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 516300</PHONE_1><FAX_1>+44 1865 516311</FAX_1></ADDRESS></PERSON><PERSON ID="3004638682E26AA20129AA21FCE7F687" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Yoon</FIRST_NAME><LAST_NAME>Loke</LAST_NAME><POSITION>Senior Lecturer in Clinical Pharmacology</POSITION><EMAIL_1>y.loke@uea.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of East Anglia</ORGANISATION><CITY>Norwich</CITY><ZIP>NR4 7TJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01603 591234</PHONE_1></ADDRESS></PERSON><PERSON ID="5475F46C82E26AA20187B79619319C6E" ROLE="AUTHOR"><FIRST_NAME>Sheena</FIRST_NAME><LAST_NAME>Derry</LAST_NAME><POSITION>Senior Research Officer</POSITION><EMAIL_1>sheena.derry@pru.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Pain Research and Nuffield Department of Anaesthetics</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>West Wing (Level 6)</ADDRESS_1><ADDRESS_2>John Radcliffe Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 234537</PHONE_1><FAX_1>+44 1865 234539</FAX_1></ADDRESS></PERSON><PERSON ID="7877" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Henry</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>McQuay</LAST_NAME><POSITION>Professor of Pain Research</POSITION><EMAIL_1>henry.mcquay@pru.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Pain Research and Nuffield Department of Anaesthetics</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>West Wing (Level 6)</ADDRESS_1><ADDRESS_2>John Radcliffe Hospital</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 231515</PHONE_1><PHONE_2>+44 1865 851138</PHONE_2><FAX_1>+44 1865 223844</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-05-28 15:17:04 +0100" MODIFIED_BY="Sheena Derry">
<UP_TO_DATE>
<DATE DAY="15" MONTH="1" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="12" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2010-07-04 14:28:55 +0200" MODIFIED_BY="Caroline Struthers"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-04 14:28:55 +0200" MODIFIED_BY="Caroline Struthers"><DATE DAY="4" MONTH="7" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2008-06-26 15:41:47 +0100" MODIFIED_BY="Jessica R Thomas">
<DATE DAY="26" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>The review authors consider that additional relevant studies are unlikely to be conducted, and that further updates of this review are unnecessary.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2010-07-04 14:28:55 +0200" MODIFIED_BY="Caroline Struthers"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-04 14:28:55 +0200" MODIFIED_BY="Caroline Struthers">
<DATE DAY="28" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-05-28 15:14:27 +0100" MODIFIED_BY="Sheena Derry">
<DATE DAY="15" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>New studies sought but none found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2008-06-26 15:42:00 +0100" MODIFIED_BY="Jessica R Thomas">
<DATE DAY="15" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Further studies satisfying our inclusion criteria were sought in MEDLINE (via Ovid), EMBASE (via Ovid) and Cochrane CENTRAL to December 2007. No further studies were identified, so the conclusions of the review are unchanged.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Oxford Pain Research Funds, Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Biotechnology and Biological Sciences Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>SmithKline Beecham Consumer Healthcare</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>European Union Biomed 2 (#BMH4-CT95-0172)</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>NHS R&amp;D Health Technology Evaluation Programmes</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>NHS Cochrane Collaboratiion Programme Grant Scheme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-28 15:20:14 +0100" MODIFIED_BY="Sheena Derry">
<SUMMARY>
<TITLE>Piroxicam as a single dose in treating acute postoperative pain</TITLE>
<SUMMARY_BODY>
<P>There is insufficient evidence that single doses of piroxicam provide effective analgesia in adults with acute postoperative pain. This review assessed the efficacy of oral single-dose piroxicam in adults with moderate/severe postoperative pain using information from randomised placebo controlled trials. The results were based on few data and were not robust. The results suggested that piroxicam (20 mg or 40 mg) was more effective than placebo and comparable to other non-steroidal anti-inflammatory drugs and intramuscular morphine 10 mg. Adverse effects were uncommon. The most frequently reported adverse effects were dizziness, nausea and vomiting.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-05-28 15:19:38 +0100" MODIFIED_BY="Sheena Derry">
<ABS_BACKGROUND>
<P>This is an updated version of the original Cochrane review published in Issue 2, 2000. Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) with analgesic properties, and is used mainly for treating rheumatic disorders. Some drugs have been directly compared against each other within a trial setting to determine their relative efficacies, whereas other have not. It is possible, however, to compare analgesics indirectly by examining the effectiveness of each drug against placebo when used in similar clinical situations.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the analgesic efficacy and adverse effects of single-dose piroxicam compared with placebo in moderate to severe postoperative pain. To compare the effects of piroxicam with other analgesics.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Published studies were identified from systematic searching of MEDLINE, Biological Abstracts, EMBASE, CENTRAL and the Oxford Pain Relief Database in December 2007. Additional studies were identified from the reference lists of retrieved reports.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>The following inclusion criteria were used: full journal publication, randomised placebo controlled trial, double-blind design, adult participants, postoperative pain of moderate to severe intensity at the baseline assessment, postoperative administration of oral or intramuscular piroxicam. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-05-28 15:19:31 +0100" MODIFIED_BY="Sheena Derry">
<P>Summed pain intensity and pain relief data were extracted and converted into dichotomous information to yield the number of participants obtaining at least 50% pain relief. This was used to calculate estimates of relative benefit and number-needed-to-treat-to-benefit (NNT) for one participant to obtain at least 50% pain relief. Information was collected on adverse effects and estimates of relative risk and number-needed-to-treat-to-harm (NNH) were calculated.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-05-28 15:19:38 +0100" MODIFIED_BY="Sheena Derry">
<P>In this update no further studies were found. The original search identified three studies (141 participants) which compared oral piroxicam 20 mg with placebo and one (15 participants) compared oral piroxicam 40 mg with placebo. For single doses of piroxicam 20 mg and 40 mg the respective NNT for at least 50% pain relief were 2.7 (2.1 to 3.8) [95% confidence interval (CI)] and 1.9 (1.2 to 4.3) [95% CI] compared with placebo over four to six hours in moderate to severe postoperative pain. The reported incidence of adverse effects was no higher with piroxicam (20 mg or 40 mg) than with placebo. No further additional studies were found in the updated search.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Piroxicam appears to be of similar efficacy to other NSAIDs and intramuscular morphine 10 mg when used as a single oral dose in the treatment of moderate to severe postoperative pain. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-28 15:20:14 +0100" MODIFIED_BY="Sheena Derry">
<BACKGROUND MODIFIED="2008-05-28 15:19:44 +0100" MODIFIED_BY="Sheena Derry">
<P>This is an update of a previously published review in the Cochrane Database of Systematic Reviews (Issue 2, 2000) on 'Single dose piroxicam for the treatment of acute postoperative pain'.</P>
<P>Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) with analgesic properties, and is used mainly for treating rheumatic disorders. In 2005, there were over 150,000 prescriptions for piroxicam in the United Kingdom (<LINK REF="REF-PACT-2006" TYPE="REFERENCE">PACT 2006</LINK>). It has been suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may be superior to opioid analgesics in some forms of postoperative pain (<LINK REF="REF-Hardman-1996" TYPE="REFERENCE">Hardman 1996</LINK>).</P>
<P>Many analgesics are available and it is often difficult determine whether one is more efficacious than another. Some drugs have been directly compared against each other within a trial setting to determine their relative efficacies, whereas other have not. It is possible, however, to compare analgesics indirectly by examining the effectiveness of each drug against placebo when used in similar clinical situations. A validated method has been derived for converting mean pain outcome values from pain intensity and pain relief scales into dichotomous information which can be used to derive the proportion of patients with at least 50% pain relief (<LINK REF="REF-Moore-1996" TYPE="REFERENCE">Moore 1996</LINK>; <LINK REF="REF-Moore-1997a" TYPE="REFERENCE">Moore 1997a</LINK>; <LINK REF="REF-Moore-1997b" TYPE="REFERENCE">Moore 1997b</LINK>). This can be used to derive estimates of relative benefit and number-needed-to-treat -to-benefit (NNT). Comparison of the NNT against placebo for different analgesics allows a rank order of relative efficacy to be established. Relative efficacy of oral analgesics after third molar extraction has been examined (<LINK REF="REF-Barden-2004" TYPE="REFERENCE">Barden 2004</LINK>).</P>
<P>This quantitative systematic review assesses the efficacy and adverse effects of single-dose piroxicam compared with placebo in the treatment of moderate to severe postoperative pain.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To quantitatively evaluate the analgesic efficacy and adverse effects of piroxicam in postoperative pain and to compare it with other analgesics assessed in the same way.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-05-28 15:19:50 +0100" MODIFIED_BY="Sheena Derry">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Studies were included if they were a full journal publication of single-dose, double-blind, randomised controlled (placebo or active) trials of piroxicam over four to six hours in postoperative pain. Multiple dose studies were included if they provided single-dose efficacy and adverse effect data. Study drugs needed to have been administered (by injection or orally) postoperatively to adult participants with moderate or severe pain at baseline. </P>
<P>Studies were excluded if they did not clearly state that study medication had been randomly allocated or if the method of randomisation was considered inappropriate (e.g. date of birth), if they examined other pain conditions (postfracture, postpartum uterine cramps, chronic pain, muscle strain, post-trauma pain).</P>
<P>Abstracts, review articles, case reports, clinical observations, and unpublished data were not sought. Neither pharmaceutical companies nor authors were contacted for unpublished reports.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies of adult participants with established baseline postoperative pain of moderate to severe intensity were included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Studies were included if they contained a treatment group where oral or intramuscular piroxicam or control was administered in the acute postoperative period. Studies with pre and perioperative dosing were excluded. Other formulations of piroxicam with different pharmacokinetic properties, such as piroxicam-ß-cyclodextrin were not considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>TOTPAR (total pain relief) or SPID (summed pain intensity difference) over four to six hours or sufficient data to allow their calculation were extracted. The pain outcome measures allowed for the calculation of TOTPAR and SPID were:<BR/>(i) a five point categorical pain relief scale with comparable wording to 'none, slight, moderate, good, complete' (scales using percentages as anchors were not permitted);<BR/>(ii) four point categorical pain intensity scale with comparable wording to 'none, mild, moderate, severe';<BR/>(iii) VAS 100 mm for pain intensity;<BR/>(iv) VAS 100 mm for pain relief.</P>
<P>For visual analogue scales (VAS) pain of at least moderate intensity equates &gt; 30 mm on a 100 mm VAS (<LINK REF="REF-Collins-1997" TYPE="REFERENCE">Collins 1997</LINK>). When the baseline pain intensity was presented as a mean VAS score with the corresponding standard deviation (SD), the study was included only if the mean minus 1.96 times the SD was &gt; 30 mm.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-05-28 15:18:20 +0100" MODIFIED_BY="Sheena Derry">
<P>The following electronic databases were searched:<BR/>Cochrane CENTRAL (Issue 3, 1999 for original review and Issue 4, 2007 for the update);<BR/>MEDLINE from 1966 to October 1999 for the original review, and MEDLINE from January 1999 to December 2007 for the update;<BR/>EMBASE from 1980 to October 1999 for the original review and January 1999 to December 2007 for the update;<BR/>the Oxford Pain Relief database (handsearch records for the years 1954 to 1995 (<LINK REF="REF-Jadad-1996a" TYPE="REFERENCE">Jadad 1996a</LINK>).<BR/>
</P>
<P>Please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the MEDLINE search strategy which was adapted for all other databases searched.<B>
<BR/>
</B>
</P>
<P>Reference lists of retrieved reports were also manually searched.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-05-28 15:19:50 +0100" MODIFIED_BY="Sheena Derry">
<P>There was no attempt at anonymisation of the studies before assessment. All selected studies were independently checked by two review authors (JE and YL) to determine their eligibility for inclusion and a consensus was reached on discrepancies. Data abstraction and quality assessments were independently carried out by two review authors (JE, YL) and rechecked by the other review authors (HJM, RAM).</P>
<P>The following data were extracted from each study:<BR/>1. number of participants treated;<BR/>2. mean TOTPAR or SPID;<BR/>3. study duration;<BR/>4. dose of piroxicam;<BR/>5. information on adverse effects;<BR/>6. information on remedication.</P>
<P>Mean TOTPAR, SPID, VAS TOTPAR and VAS SPID values were converted to %maxTOTPAR or %maxSPID by division into the calculated maximum value (<LINK REF="REF-Moore-1996" TYPE="REFERENCE">Moore 1996</LINK>). Verified equations were used to estimate the proportion of participants achieving at least 50% maxTOTPAR (<LINK REF="REF-Moore-1997a" TYPE="REFERENCE">Moore 1997a</LINK>; <LINK REF="REF-Moore-1997b" TYPE="REFERENCE">Moore 1997b</LINK>). This was then converted to the number of participants achieving at least 50% maxTOTPAR by multiplying by the total number of participants in the treatment group. The number of participants with at least 50% maxTOTPAR was then used to calculate estimates of relative benefit and NNT.</P>
<P>Relative benefit and relative risk estimates with 95% CI were calculated using the fixed-effect model (<LINK REF="REF-Morris-1995" TYPE="REFERENCE">Morris 1995</LINK>). Heterogeneity was tested using a chi-squared test; homogeneity was assumed when P &gt; 0.1. When the lower limit of the 95% confidence interval (CI) for the relative benefit was &gt;1, a statistically significant benefit of active treatment over placebo was assumed. Conversely, when the upper limit of the 95% CI for the relative benefit was &lt; 1, a statistically significant benefit of placebo over active treatment was assumed. NNT with 95% CIs were calculated with Excel v 5.0 on a Macintosh Performa 6320 (<LINK REF="REF-Cook-1995" TYPE="REFERENCE">Cook 1995</LINK>). No benefit of one treatment over another was assumed if the upper limit of the CI extended to infinity.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-05-28 15:19:56 +0100" MODIFIED_BY="Sheena Derry">
<STUDY_DESCRIPTION>
<P>Seventy-one studies were identified as potential studies of piroxicam in postoperative pain; three (<LINK REF="STD-Alpaslan-1997" TYPE="STUDY">Alpaslan 1997</LINK>; <LINK REF="STD-Barbieri-1982" TYPE="STUDY">Barbieri 1982</LINK>; <LINK REF="STD-Frezza-1985" TYPE="STUDY">Frezza 1985</LINK>) could not be obtained from the British Library. Of the obtained reports, 11 were reviews or abstracts and were excluded. </P>
<P>A further 55 studies were excluded for the following reasons: in 16 piroxicam was not administered or participants was assessed in the postoperative period, 11 studies either did not assess the baseline pain intensity of participants or included mild pain, five had no placebo group, five were noncomparative studies, four were not randomised, four did not assess postoperative pain or included other pain conditions (e.g. trauma), three had no extractable data, two were duplicate publications, one was not double blind, one did not assess the analgesic properties of piroxicam, and one included remedicators in the analyses without adjusting the pain scores (<LINK REF="STD-Breivik-1984" TYPE="STUDY">Breivik 1984</LINK>). Two other studies assessed a fast-dissolving formulation of piroxicam (<LINK REF="STD-Selcuk-1998" TYPE="STUDY">Selcuk 1998</LINK>; <LINK REF="STD-Sencift-1997" TYPE="STUDY">Sencift 1997</LINK>) and were excluded because they did not use a placebo comparator group.</P>
<P>Only two reports of three studies (548 participants in total) met the criteria for inclusion in this systematic review (<LINK REF="STD-Dolci-1994" TYPE="STUDY">Dolci 1994</LINK>; <LINK REF="STD-Sunshine-1988a" TYPE="STUDY">Sunshine 1988a</LINK>; <LINK REF="STD-Sunshine-1988b" TYPE="STUDY">Sunshine 1988b</LINK>). Of these, one was made up of two separate studies (<LINK REF="STD-Sunshine-1988a" TYPE="STUDY">Sunshine 1988a</LINK>; <LINK REF="STD-Sunshine-1988b" TYPE="STUDY">Sunshine 1988b</LINK>) both parts of which fulfilled the inclusion criteria. These studies assessed oral piroxicam. No studies assessing intramuscular piroxicam fulfilled the inclusion criteria (two used piroxicam preoperatively, and in one study participants did not have moderate to severe pain at baseline). No additional studies were identified in the updated searches.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Each study was scored for quality by the three review authors using a three-item scale (see below) (<LINK REF="REF-Jadad-1996b" TYPE="REFERENCE">Jadad 1996b</LINK>) a 'consensus' score was agreed for each study. The quality scores for individual studies are reported in the 'Characteristics of included studies' table. These scores were not used to weight the results in any way. </P>
<P>The three item scale is as follows:<BR/> Is the study randomised? If yes then 1 point <BR/> Is the randomisation procedure reported and is it appropriate? If yes then add 1 point, if not deduct 1 <BR/> Is the study double blind? If yes then 1 point <BR/> Is the double blind method reported and is it appropriate? If yes then add 1 point, if not deduct 1 <BR/> Are withdrawals and dropouts described? If yes add 1 point</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-05-28 15:19:56 +0100" MODIFIED_BY="Sheena Derry">
<P>One study (<LINK REF="STD-Sunshine-1988a" TYPE="STUDY">Sunshine 1988a</LINK>; <LINK REF="STD-Sunshine-1988b" TYPE="STUDY">Sunshine 1988b</LINK>) assessed participants who had undergone general and gynaecological surgical procedures, the other (<LINK REF="STD-Dolci-1994" TYPE="STUDY">Dolci 1994</LINK>) assessed participants after dental operations. These studies assessed piroxicam 20 mg (141 participants) against placebo (139 participants), and piroxicam 40 mg (15 participants) against placebo (15 participants). No additional studies were identified in the updated searches.</P>
<P>The response rate for 20 mg of piroxicam (proportion of participants experiencing at least 50% pain relief with piroxicam 20 mg) varied between 30% to 82% and that for placebo varied between 15% to 33%. For a single dose of piroxicam 20 mg the relative benefit was 2.5 (1.8 to 3.3) and the NNT was 2.7 (2.1 to 3.8) for at least 50% pain relief compared with placebo over a period of four to six hours in moderate to severe postoperative pain. There was no significant heterogeneity found (P = 0.8).</P>
<P>Information from 15 participants only was available for piroxicam 40 mg, with a response rate of 80% compared with a placebo response rate of 27%. For a single dose of piroxicam 40 mg, the relative benefit was 3.0 (1.3 to 7.2) and the NNT was 1.9 (1.2 to 4.3) for at least 50% pain relief compared with placebo over four to six hours in moderate to severe postoperative pain.</P>
<P>No data was identified for remedication.</P>
<P>
<B>Adverse Effects</B>
<BR/>All three studies reported the occurrence of adverse effects, although none specifically categorised the severity of the adverse effects. Fever was classed as an adverse effect and was commonly reported in one study (<LINK REF="STD-Sunshine-1988a" TYPE="STUDY">Sunshine 1988a</LINK>; <LINK REF="STD-Sunshine-1988b" TYPE="STUDY">Sunshine 1988b</LINK>), but rarely in the other. Three participants withdrew from the individual studies because of adverse effects; all had received placebo. Two withdrawals were due to fever and the other with fever, nausea and diarrhoea.</P>
<P>
<B>
<I>Fever: </I>
</B>
<BR/>This was reported by 4/141 (3%) of participants on piroxicam 20 mg and 20/141 (14%) on placebo. Significantly fewer participants reported fever with piroxicam than placebo, relative risk 0.2 (0.1 to 0.6) and number-needed-to-treat-to-harm (NNH) -9 (-20 to -5).</P>
<P>
<B>
<I>Non-fever adverse events: </I>
</B>
<BR/>A total of 6/141 (4%) on piroxicam 20 mg and 18/141 (13%) on placebo reported adverse effects other than fever. Significantly fewer participants reported non-fever adverse effects with piroxicam than placebo, relative risk 0.3 (01 to 0.8) and NNH -12 (-7 to -48).</P>
<P>The most commonly reported non-fever adverse effects with placebo were dizziness (seven), nausea and vomiting (five), headache (four), sweating (two) and tachycardia (two).</P>
<P>When the data for fever and other adverse effects were pooled together, participants given piroxicam 20 mg were significantly less likely to report any adverse effects compared with those given placebo; relative risk 0.26 (0.1 to 0.5) and NNH -5 (-3 to -9).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-05-28 15:20:12 +0100" MODIFIED_BY="Sheena Derry">
<P>Two doses of piroxicam (20 mg and 40 mg) were assessed, though limited participant data were available for analysis, particularly for piroxicam 40 mg. For a single oral dose of piroxicam 20 mg the NNT for at least 50% pain relief was 2.7 (2.1 to 3.8) for moderate to severe postoperative pain over four to six hours. This means that one in every three patients with moderate to severe postoperative pain would obtain at least 50% pain relief with piroxicam 20 mg who would not have done with placebo. Similarly, for single-dose piroxicam 40 mg the NNT was 1.9 (1.2 to 4.3). The NNTs suggest a dose-response for efficacy, but because of overlapping CIs and limited participant information this conclusion is not robust.</P>
<P>The NNTs derived for piroxicam appear to show that it is an effective analgesic for treating moderate or severe postoperative pain. A rank order of the efficacy of different analgesics compared with placebo exists which allows comparison between different analgesics. This has been published previously in its entirety (<LINK REF="REF-McQuay-1998" TYPE="REFERENCE">McQuay 1998</LINK>) and for third molar extraction studies only (<LINK REF="REF-Barden-2004" TYPE="REFERENCE">Barden 2004</LINK>). It is also available on the World Wide Web: http://www.jr2.ox.ac.uk/bandolier/painres/painpag/Acutrev/Analgesics/Leagtab.html, or from the review authors. This rank order shows that piroxicam has a lower (better) NNT than paracetamol 1000 mg and the opioid analgesics codeine 60 mg, dextropropoxyphene 65 mg plus paracetamol 650 mg and tramadol 75 mg (<LINK REF="REF-Collins-1998" TYPE="REFERENCE">Collins 1998</LINK>; <LINK REF="REF-Moore-1997c" TYPE="REFERENCE">Moore 1997c</LINK>; <LINK REF="REF-Moore-1997d" TYPE="REFERENCE">Moore 1997d</LINK>). Its efficacy is comparable to that of other NSAIDs, for example ibuprofen and diclofenac (<LINK REF="REF-Collins-1999" TYPE="REFERENCE">Collins 1999</LINK>).</P>
<P>Single dose piroxicam has been reported to be reasonably free from major adverse effects (<LINK REF="STD-Meisel-1986" TYPE="STUDY">Meisel 1986</LINK>). This systematic review showed significantly fewer adverse effects with piroxicam 20 mg than with placebo. Although this seems to suggest that piroxicam is safer than placebo there are a number of reasons why this conclusion may be wrong.</P>
<P>Firstly, it is not clear from the <LINK REF="STD-Sunshine-1988a" TYPE="STUDY">Sunshine 1988a</LINK>/<LINK REF="STD-Sunshine-1988b" TYPE="STUDY">Sunshine 1988b</LINK> study whether the occurrence of fever was objectively confirmed or from subjective, unverified reports by participants who may merely have stated that they were feeling hot. Postoperative patients do genuinely develop fevers for a number of reasons; some related to the anaesthetic techniques and surgical handling, others due to infective complications. Piroxicam also has anti-pyretic properties (<LINK REF="REF-Hardman-1996" TYPE="REFERENCE">Hardman 1996</LINK>) and would have acted to reduce the number of participants experiencing fevers. Thus it would be misleading to look for fever as an adverse effect.</P>
<P>Secondly, participants treated with placebo may have reported a significant excess of other (non-fever) adverse effects because they were in pain and had obtained little relief from the allocated treatment. It would not be unusual for participants experiencing moderate to severe pain to have additional symptoms such as nausea, sweating and tachycardia, which are manifestations of the sympathetic nervous system 'stress' response to pain. The excess number of headaches in participants on placebo could be explained by the fact that the analgesic properties of piroxicam had relieved the headaches of the participants in the treated group.</P>
<P>Thirdly, the ability to pool together adverse effect data was limited by the lack of participant data and a lack of detailed information on how they were defined, collected and reported (<LINK REF="REF-Edwards-1999" TYPE="REFERENCE">Edwards 1999</LINK>). This is in marked contrast to the methodologically rigorous nature by which efficacy data were extracted. Given all the above issues, any conclusions on adverse effects should be viewed with caution.</P>
<P>The relative paucity of data was the main limitation of this systematic review. Only three studies were of adequate quality for inclusion. This is despite the use of a broad search strategy with no language limitations, and hand searching of references from retrieved studies. Our main objective was to derive a common descriptor for comparing relative analgesic efficacies. It was, therefore, important to adhere to the same rigorous methods used in the previous systematic reviews of single dose postoperative analgesia (<LINK REF="REF-Collins-1998" TYPE="REFERENCE">Collins 1998</LINK>; <LINK REF="REF-Moore-1997c" TYPE="REFERENCE">Moore 1997c</LINK>; <LINK REF="REF-Moore-1997d" TYPE="REFERENCE">Moore 1997d</LINK>). Studies in which participants do not experience established pain lack sensitivity (<LINK REF="REF-Lasagna-1962" TYPE="REFERENCE">Lasagna 1962</LINK>). Sixteen studies were excluded because piroxicam was administered pre and perioperatively, or because the assessment of pain was carried out over a number of days rather than in the acute postoperative setting. The method for generating dichotomous data used in this review has been verified for standard pain outcome scales and for four to six hours treatment duration after a postoperative intervention.</P>
<P>Despite the fact that only three studies (from two reports) were included in this review, the data appeared robust for the efficacy assessment, though superiority of the higher 40 mg dose over the 20 mg dose could not be substantiated.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-05-28 15:20:14 +0100" MODIFIED_BY="Sheena Derry">
<IMPLICATIONS_PRACTICE MODIFIED="2008-05-28 15:20:14 +0100" MODIFIED_BY="Sheena Derry">
<P>The update of this review has not identified any further information to provide evidence for or against the use of 'Single dose piroxicam for acute postoperative pain'. There remains insufficient high quality information available on which to make purchasing or policy decisions. However, the NNTs suggest that single doses of piroxicam (20 mg and 40 mg) are reasonably effective for treating moderate to severe postoperative pain, and compare favourably with opioid analgesics such as dextropropoxyphene and tramadol, and other NSAIDs. Few adverse effects were reported and piroxicam appears to be fairly well tolerated in this clinical context. In multiple dosing the adverse effect profile may be more prominent. There is a definite need to be able to quantitatively assess the efficacy and adverse effects of piroxicam in prolonged dosing regimens.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further work is required to reliably assess the relative efficacy and safety of piroxicam under well controlled conditions, particularly intramuscular piroxicam. Study designs should include systematic, well defined methods for collecting and reporting adverse effects.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank Claire Abbott at the Cairns Library, Churchill Hospital for her help and support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>YKL and SD have no interests to declare. RAM has been a consultant for MSD. RAM and HJM have consulted for various pharmaceutical companies. RAM, HJM and JR have received lecture fees from pharmaceutical companies related to analgesics and other healthcare interventions. All authors have received research support from charities, government and industry sources at various times: no such support was received for this work.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Original review<BR/>JR and YL were involved with searching, data extraction, analysis and writing. AM and HJM were involved with analysis and writing.</P>
<P>Update 2008<BR/>SD and AM carried out the searching and writing.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>The review authors consider that additional relevant studies are unlikely to be conducted, and that further updates of this review are unnecessary and therefore this review is unlikely to require further update.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-05-28 15:21:21 +0100" MODIFIED_BY="Sheena Derry">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolci-1994" NAME="Dolci 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolci G, Ripari M, Pacifici L, Umile A</AU>
<TI>Evaluation of piroxicam-beta-cyclodextrin, piroxicam, paracetamol and placebo in postoperative oral surgery pain</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>185-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunshine-1988a" NAME="Sunshine 1988a" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunshine A, Roure C, Colon A, Olson, NZ, Gonzalez L, Siegel C, et al</AU>
<TI>Analgesic efficacy of piroxicam in the treatment of postoperative pain</TI>
<SO>The American Journal of Medicine</SO>
<YR>1988</YR>
<VL>84</VL>
<NO>5A</NO>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunshine-1988b" NAME="Sunshine 1988b" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunshine A, Roure C, Colon A, Olson, NZ, Gonzalez L, Siegel C, et al</AU>
<TI>Analgesic efficacy of piroxicam in the treatment of postoperative pain</TI>
<SO>The American Journal of Medicine</SO>
<YR>1988</YR>
<VL>84</VL>
<NO>5A</NO>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Alpaslan-1997" NAME="Alpaslan 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alpaslan C, Alpaslan G, Ugar D</AU>
<TI>Postoperative pain control by single doses of piroxicam administered sublingually and aspirin</TI>
<SO>Journal of Marmara University Dental Faculty</SO>
<YR>1997</YR>
<VL>2</VL>
<NO>4</NO>
<PG>658-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1993" NAME="Anderson 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson P, Lysak SZ, Carithers RA, DeVane G, Smith ML, Bates GW</AU>
<TI>Efficacy of fentanyl, ketorolac and piroxicam for postoperative analgesia</TI>
<SO>Journal of the American Association of Nurse Anesthetists</SO>
<YR>1993</YR>
<VL>61</VL>
<NO>4</NO>
<PG>427-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1995" NAME="Anonymous 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;English title not available&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Heeft Brexine(r) voordelen boven andere pijnstillers</TI>
<SO>Geneesmiddelenbulletin</SO>
<YR>1995</YR>
<VL>29</VL>
<NO>3</NO>
<PG>30-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arvidsson-1987" NAME="Arvidsson 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arvidsson I, Eriksson E</AU>
<TI>A double blind trial of NSAID double blind trial of NSAID versus placebo during rehabilitation</TI>
<SO>Orthopedics</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>7</NO>
<PG>1007-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbieri-1982" NAME="Barbieri 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbieri E, Pannone G, Arosio A, Santilli A</AU>
<TI>A comparison in the orthopedic-traumatologic field between the analgesic effect of piroxicam and ibuprofen, two non-steroidal anti-inflammatory drugs (NSAIDS)</TI>
<SO>Terapie Essenziali in Clinica</SO>
<YR>1982</YR>
<VL>2</VL>
<PG>283-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bauduin-1995" NAME="Bauduin 1995" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauduin H, Famaey JP</AU>
<TI>Comparison of the analgesic effects of beta-cyclodextrin-piroxicam, sodium naproxen and potassium diclofenac utilizing the dental pain model</TI>
<SO>Journal of Pharmaceutical Care in Pain and Symptom Control</SO>
<YR>1995</YR>
<VL>3</VL>
<NO>2</NO>
<PG>19-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bigler-1992" NAME="Bigler 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bigler D, Moller J, Kamp Jensen M, Berthelsen P, Hjortso NC, Kehlet H</AU>
<TI>Effect of piroxicam in addition to continuous thoracic epidural bupivacaine and morphine on postoperative pain and lung function after thoracotomy</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1992</YR>
<VL>36</VL>
<NO>7</NO>
<PG>647-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boeckstyns-1992" NAME="Boeckstyns 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boeckstyns MEH, Backer M, Petersen EM, Hoj I, Albrechtsen H, Andersen HB</AU>
<TI>Piroxicam spares buprenorphine after total joint replacement. Controlled study of pain treatment in 81 patients</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>1992</YR>
<VL>63</VL>
<NO>6</NO>
<PG>658-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breivik-1984" NAME="Breivik 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breivik H, Stenseth R, Apalseth K, Spilsberg AM</AU>
<TI>Piroxicam, acetylsalicylic acid and placebo for postoperative pain</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1984</YR>
<VL>28</VL>
<NO>1</NO>
<PG>37-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruno-1987" NAME="Bruno 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruno E</AU>
<TI>Not available</TI>
<TO>Il dolore post-estravattivo. Trattamento analgesico con piroxicam</TO>
<SO>Dental Cadmos</SO>
<YR>1987</YR>
<VL>55</VL>
<PG>14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Celenza-1995" NAME="Celenza 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Celenza M, Pillone P, Longeri A, Cremonesi G</AU>
<TI>Piroxicam-beta-cyclodextrin vs ketorolac-tromethamine in the treatment of post-surgical pain</TI>
<SO>Gazzetta Medica Italiana Archivio Per Le Scienze Mediche</SO>
<YR>1995</YR>
<VL>154</VL>
<NO>2</NO>
<PG>81-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruz-1984" NAME="Cruz 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruz R</AU>
<TI>An oral analgesic study of piroxicam (feldene) in post-operative dental pain</TI>
<SO>Current Therapeutic Research</SO>
<YR>1984</YR>
<VL>36</VL>
<PG>1256-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeAndrade-1994" NAME="DeAndrade 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeAndrade JR, Maslanka M, Maneatis T, Bynum L, Burchmore M</AU>
<TI>The use of ketorolac in the management of postoperative pain</TI>
<SO>Orthopedics</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>2</NO>
<PG>157-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Desjardins-1988" NAME="Desjardins 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desjardins PJ</AU>
<TI>Analgesic efficacy of piroxicam in postoperative dental pain</TI>
<SO>The American Journal of Medicine</SO>
<YR>1988</YR>
<VL>84</VL>
<NO>5A</NO>
<PG>35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Desjardins-1990" NAME="Desjardins 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desjardins PJ, Iranpour B, Handelman S, Emmings F</AU>
<TI>Piroxicam in dental pain</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>2</NO>
<PG>163</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolci-1993" NAME="Dolci 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolci G, Ripari M, Pacifici L, Umile A</AU>
<TI>[Analgesic efficacy and the tolerance for piroxicam-beta-cyclodextrin compared to piroxicam, paracetamol and placebo in the treatment of postextraction dental pain]</TI>
<SO>Minerva Stomatologica</SO>
<YR>1993</YR>
<VL>42</VL>
<NO>5</NO>
<PG>235-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fasting-1992" NAME="Fasting 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fasting OJ, Uppheim G, Thoresen BO</AU>
<TI>[Piroxicam in arthroscopic surgery of the knee. A prospective randomised double-blind multicenter study with preoperative and short term postoperative treatment]</TI>
<SO>Tidsskrift for Den Norske Laegeforening</SO>
<YR>1992</YR>
<VL>112</VL>
<NO>9</NO>
<PG>1161-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frezza-1985" NAME="Frezza 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frezza R, Bolognesi P, Bernardi F</AU>
<TI>Comparison of the action of 3 non-steroidal anti-inflammatory agents in the control of post-operative pain. Effectiveness of NSAID against pain</TI>
<SO>Attualita Dentale</SO>
<YR>1985</YR>
<VL>1</VL>
<PG>40-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilvano-1984" NAME="Hilvano 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hilvano S</AU>
<TI>A non-comparative study of the analgesic activity of piroxicam (feldene) in patients with post-operative pain following minor surgery</TI>
<SO>Current Therapeutic Research</SO>
<YR>1984</YR>
<VL>36</VL>
<PG>1269-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hutchison-1990" NAME="Hutchison 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hutchison GL, Crofts SL, Gray IG</AU>
<TI>Preoperative piroxicam for postoperative analgesia in dental surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1990</YR>
<VL>65</VL>
<NO>4</NO>
<PG>500-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jain-1978" NAME="Jain 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jain AK, McMahon FG, Ryan JR, Raphan H, Richard W</AU>
<TI>Piroxicam, a novel analgesic in postpartum pain</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1978</YR>
<VL>1</VL>
<PG>356-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jonsson-1990" NAME="Jonsson 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jonsson T, Rude C, Randberg FA, Johansen T, Lang-Jenson T, Jensen NH</AU>
<TI>Postoperative pain treated with piroxicam and buprenorphine, each drug alone or in a combination</TI>
<SO>Pain</SO>
<YR>1990</YR>
<VL>41</VL>
<NO>Supplement 1</NO>
<PG>S138</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakutani-1983" NAME="Kakutani 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakutani K</AU>
<TI>[BAXO (piroxicam) for minor postsurgical pain in the oral area]</TI>
<SO>Shikai Tenbo = Dental outlook</SO>
<YR>1983</YR>
<VL>62</VL>
<NO>1</NO>
<PG>205-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kavanagh-1994" NAME="Kavanagh 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kavanagh BP, Katz J, Sandler AN</AU>
<TI>Pain control after thoracic surgery: A review of current techniques</TI>
<SO>Anesthesiology</SO>
<YR>1994</YR>
<VL>81</VL>
<NO>3</NO>
<PG>737-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laska-1987" NAME="Laska 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laska E, Sunshine A, Colon A, Olson N, Siegel C</AU>
<TI>Piroxicam, aspirin and placebo in postoperative pain</TI>
<SO>Pain</SO>
<YR>1987</YR>
<VL>30</VL>
<NO>Supplement 1</NO>
<PG>S55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lysak-1994" NAME="Lysak 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lysak SZ, Anderson PT, Carithers RA, DeVane GG, Smith ML, Bates GW</AU>
<TI>Postoperative effects of fentanyl, ketorolac, and piroxicam as analgesics for outpatient laparoscopic procedures</TI>
<SO>Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>83</VL>
<NO>2</NO>
<PG>270-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcucci-1991" NAME="Marcucci 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcucci M, Panelli G, Cambini S</AU>
<TI>Clinical experience in the treatment of dental pain</TI>
<SO>The Clinical Journal of Pain</SO>
<YR>1991</YR>
<VL>7 (suppl)</VL>
<PG>S72-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massart-1986" NAME="Massart 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massart P, Bezes H</AU>
<TI>Comparison of the efficacy and tolerance of isoxicm and piroxicam following surgery for ski-ing accidents</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>22</VL>
<PG>161S-5S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meisel-1986" NAME="Meisel 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meisel AD</AU>
<TI>Clinical benefits and comparative safety of piroxicam. Analysis of worldwide clinical trials data</TI>
<SO>The American Journal of Medicine</SO>
<YR>1986</YR>
<VL>81</VL>
<NO>5B</NO>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melzsack-1985" NAME="Melzsack 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melzsack R, Bentley K, Jeans ME</AU>
<TI>Piroxicam versus acetaminophen and placebo for the relief of postoperative dental pain</TI>
<SO>Current Therapeutic Research</SO>
<YR>1985</YR>
<VL>37</VL>
<PG>1134-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michelacci-1990" NAME="Michelacci 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michelacci M, Boscarino G, Acerbi D, Bufalino L, Gardini F</AU>
<TI>Analgesic effect and pharmacokinetics of a piroxicam beta-cyclodextrin oral formulation in post-surgical pain: A controlled study versus an injectable piroxicam formulation</TI>
<SO>Clinical Trials Journal</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>3</NO>
<PG>176-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mogensen-1990" NAME="Mogensen 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mogensen T, Vegger P, Jonsson T, Matzke AE, Lund C, Kehlet H</AU>
<TI>Systemic piroxicam as an adjunct to combined epidural bupivacaine and morphine for postoperative pain - a double-blind study</TI>
<SO>Pain</SO>
<YR>1990</YR>
<VL>S138</VL>
<PG>S138</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mogensen-1992" NAME="Mogensen 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mogensen T, Vegger P, Jonsson T, Matzke AE, Lund C, Kehlet H</AU>
<TI>Systemic piroxicam as an adjunct to combined epidural bupivacaine and morphine for postoperative pain relief - a double-blind study</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1992</YR>
<VL>74</VL>
<PG>366-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moiniche-1994" NAME="Moiniche 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moiniche S, Hjortso NC, Hansen BL, Dahl JB, Rosenberg J, Gebuhr P, et al</AU>
<TI>The effect of balanced analgesia on early convalescence after major orthopaedic surgery</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1994</YR>
<VL>38</VL>
<NO>4</NO>
<PG>328-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moraes-1991" NAME="Moraes 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moraes MF, Antonini RA</AU>
<TI>Use of piroxicam im in buccomaxillofacial surgery</TI>
<SO>Folha Medica</SO>
<YR>1991</YR>
<VL>102</VL>
<NO>1-2</NO>
<PG>39-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrow-1995" NAME="Morrow 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrow BC, Milligan KR, Murthy BV</AU>
<TI>Analgesia following day-case knee arthroscopy - the effect of piroxicam with or without bupivacaine infiltration</TI>
<SO>Anaesthesia</SO>
<YR>1995</YR>
<VL>50</VL>
<NO>5</NO>
<PG>461-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Negm-1989" NAME="Negm 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Negm MM</AU>
<TI>Management of endodontic pain with nonsteroidal anti inflammatory agents: a double blind, placebo controlled study</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1989</YR>
<VL>67</VL>
<NO>1</NO>
<PG>88-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Negm-1994" NAME="Negm 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Negm MM</AU>
<TI>Effect of intracanal use of nonsteroidal anti-inflammatory agents on post treatment endodontic pain</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1994</YR>
<VL>77</VL>
<NO>5</NO>
<PG>507-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-1986" NAME="Nelson 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nelson SL, Bergman SA</AU>
<TI>Double-blind, parallel study of the efficacy and safety of piroxicam in the relief of post-operative pain following dental extraction</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1986</YR>
<VL>39</VL>
<NO>2</NO>
<PG>216</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-1987" NAME="Nelson 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nelson SL, Brahim J, Treglown S</AU>
<TI>Double blind study of piroxicam (2 doses), Aspirin and placebo in patients with postoperative dental pain</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1987</YR>
<VL>41</VL>
<NO>2</NO>
<PG>182</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Hanlon-1996a" NAME="O'Hanlon 1996a" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Hanlon JJ, Beers H, Huss BK, Milligan KR</AU>
<TI>A comparison of the effect of intramuscular diclofenac, ketorolac or piroxicam on post-operative pain following laparoscopy</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>4</NO>
<PG>404-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Hanlon-1996b" NAME="O'Hanlon 1996b" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Hanlon JJ, McCleane G, Muldoon T</AU>
<TI>Preoperative application of piroxicam gel compared to a local anaesthetic field block for postoperative analgesia</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>6</NO>
<PG>715-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Hanlon-1996c" NAME="O'Hanlon 1996c" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Hanlon JJ, Muldoon T, Lowry D, McCleane G</AU>
<TI>Improved postoperative analgesia with preoperative piroxicam</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>1996</YR>
<VL>43</VL>
<NO>2</NO>
<PG>102-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogunbode-1987" NAME="Ogunbode 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogunbode O</AU>
<TI>A comparative trial of piroxicam and paracetamol after episiotomy wound repair</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1987</YR>
<VL>41</VL>
<NO>1</NO>
<PG>89-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohnishi-1981" NAME="Ohnishi 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohnishi MH</AU>
<TI>The clinical effect of piroxicam on postexodontic or postoperative pain - a double blind study</TI>
<SO>Japanese Journal of Oral Surgery</SO>
<YR>1981</YR>
<VL>27</VL>
<PG>532-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohnishi-1983a" NAME="Ohnishi 1983a" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohnishi M, Kawai T, Ogawa N</AU>
<TI>Double blind evaluation of piroxicam and indomethacin in the treatment of inflammation following oral surgery</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>3</NO>
<PG>259-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohnishi-1983b" NAME="Ohnishi 1983b" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohnishi M, Kawai T, Ogawa N</AU>
<TI>Double-blind comparison of piroxicam and mefanamic acid in the treatment of oral surgical pain</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>3</NO>
<PG>253-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olson-1987" NAME="Olson 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olson N, Sunshine A, Marrero I, Ramos I, Laska E</AU>
<TI>Piroxicam, aspirin and placebo in dental pain</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1987</YR>
<VL>41</VL>
<NO>2</NO>
<PG>162</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parsloe-1988" NAME="Parsloe 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parsloe M, Chater SN, Bembridge M, Simpson KH</AU>
<TI>Premedication with piroxicam in patients having dental surgery under general anaesthesia with halothane or isoflurane</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1988</YR>
<VL>61</VL>
<NO>6</NO>
<PG>702-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pase-1986" NAME="Pase 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pase U</AU>
<TI>Use of piroxicam in dentistry</TI>
<SO>Giornale di Stomatologia e di Ortognatodonzia</SO>
<YR>1986</YR>
<VL>1</VL>
<PG>67-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-1996" NAME="Patel 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel RK, Leswell PF</AU>
<TI>Comparison of ketoprofen, piroxicam, and diclofenac gels in the treatment of acute soft-tissue injury in general practice. General Practice Study Group</TI>
<SO>Clinical Therapeutics</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>3</NO>
<PG>497-507</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piironen-1985" NAME="Piironen 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piironen J, Sjoblad AM, Oikarinen VJ</AU>
<TI>The analgesic efficacy of one preoperative and postoperative dose of piroxicam in oral surgery</TI>
<SO>Proceedings Of The Finnish Dental Society</SO>
<YR>1985</YR>
<VL>81</VL>
<NO>5-6</NO>
<PG>271-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roelofse-1996" NAME="Roelofse 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roelofse JA, Swart LC, Stander IA</AU>
<TI>An observer-blind randomised parallel group study comparing the efficacy and tolerability of tenoxicam and piroxicam in the treatment of post-operative pain after oral surgery</TI>
<SO>The Journal of the Dental Association of South Africa</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>11</NO>
<PG>707-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Selcuk-1998" NAME="Selcuk 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selcuk E, Gomel M, Apaydin S, Kose T, Tuglular I</AU>
<TI>The postoperative analgesic efficacy and safety of piroxicam (FDDF) and naproxen sodium</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>1</NO>
<PG>21-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sencift-1997" NAME="Sencift 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sencift K, Akkocaoglu M, Turkes O, Araz K</AU>
<TI>The clinical effects of fast dissolving dosage form of piroxicam in impacted third molar surgery</TI>
<SO>The Journal of The Turkish Society of Algology</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>1</NO>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serpell-1989" NAME="Serpell 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serpell MG, Thomson MF</AU>
<TI>Comparison of piroxicam with placebo in the management of pain after total hip replacement</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1989</YR>
<VL>63</VL>
<NO>3</NO>
<PG>354-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simone-1990" NAME="Simone 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simone C, Oliani C</AU>
<TI>Beta-cyclodextrin-piroxicam: Efficacy and tolerability in the treatment of pain after bone and joint surgery</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>3</NO>
<PG>541-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singson_x002d_Alday-1984" NAME="Singson-Alday 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singson-Alday</AU>
<TI>A study of the analgesic activity of piroxicam (feldene) in patients with post episiotomy pain</TI>
<SO>Current Therapeutic Research</SO>
<YR>1984</YR>
<VL>36</VL>
<PG>1261-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunshine-1995a" NAME="Sunshine 1995a" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunshine A, Marrero I, Mcmoemick N, Lawrence V, Gafney M, Ackert P</AU>
<TI>The analgesic efficacy of piroxicam, aspirin and placebo in postoperative oral surgery pain</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1995</YR>
<VL>37</VL>
<NO>2</NO>
<PG>232</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunshine-1995b" NAME="Sunshine 1995b" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunshine A</AU>
<TI>Analgesia induced by oral NSAIDs: Issues of relative efficacy</TI>
<SO>European Journal of Rheumatology and Inflammation</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>2</NO>
<PG>19-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taboada-1992" NAME="Taboada 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taboada A</AU>
<TI>Not available</TI>
<TO>Experienca controlada con gel de piroxicam asociado a ultrasonidos en afecciones agudas del aparto locomotor</TO>
<SO>Prensa Medica Argentina</SO>
<YR>1992</YR>
<VL>79</VL>
<PG>630-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teixeira-1993" NAME="Teixeira 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teixeira F, Porto A, Moura J</AU>
<TI>Efficacy of a single daily dose of a nonsteroidal anti-inflammatory drug with an intermediate plasma half-life: A double-blind, comparative trial of acemetacin and piroxicam</TI>
<SO>Current Therapeutic Research</SO>
<YR>1993</YR>
<VL>53</VL>
<NO>1</NO>
<PG>103-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Utsunomiya-1983" NAME="Utsunomiya 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Utsunomiya Y, Sotoike H, Shirosawa T, Kamata N, Omori N</AU>
<TI>[Analgesic effect of Feldene (piroxicam) on pain following minor oral surgery]</TI>
<SO>Shikai Tenbo = Dental outlook</SO>
<YR>1983</YR>
<VL>62</VL>
<NO>4</NO>
<PG>835-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vagnoni-1990" NAME="Vagnoni 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vagnoni S, Rodola F, Stancanelli V, Barbi S, Mascaro A, Camaioni D</AU>
<TI>Postoperative analgesia in open-chest surgery</TI>
<SO>Ortopedia e Traumatologia Oggi</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>6</NO>
<PG>369-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Lackner-1996" NAME="Van Lackner 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Lancker P, Devulder J, Rolly G</AU>
<TI>Systemic piroxicam as an adjunct to patient-controlled analgesia with alfentanil for postoperative pain relief</TI>
<SO>Anaesthesia</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>7</NO>
<PG>658-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wakeling-1996" NAME="Wakeling 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wakeling HG, Creagh Barry P, Butler PJ</AU>
<TI>Postoperative analgesia in dental day case surgery. Comparison between Feldene 'Melt' (piroxicam) and diclofenac suppositories</TI>
<SO>Anaesthesia</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>8</NO>
<PG>784-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yagi-1997" NAME="Yagi 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yagi Y, Sakaguchi H, Noda M, et al</AU>
<TI>Postoperative pain management after head and neck surgery</TI>
<SO>Journal of Japanese Dental Society of Anesthesiology</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>2</NO>
<PG>163-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshimasu-1983" NAME="Yoshimasu 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshimasu H, Yoshikane K, Nakano Y, Iwata J, Yokoo E</AU>
<TI>[An anti-inflammatory analgesic, Feldene (piroxicam), for pain following tooth extraction - clinical results]</TI>
<SO>Shikai Tenbo = Dental outlook</SO>
<YR>1983</YR>
<VL>62</VL>
<NO>4</NO>
<PG>829-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-28 15:21:21 +0100" MODIFIED_BY="Sheena Derry">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-28 15:21:21 +0100" MODIFIED_BY="Sheena Derry">
<REFERENCE ID="REF-Barden-2004" NAME="Barden 2004" TYPE="JOURNAL_ARTICLE">
<AU>Barden J, Edwards JE, McQuay HJ, Wiffen PJ, Moore RA</AU>
<TI>Relative efficacy of oral analgesics after third molar extraction</TI>
<SO>British Dental Journal</SO>
<YR>2004</YR>
<VL>197</VL>
<NO>7</NO>
<PG>407-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1997" NAME="Collins 1997" TYPE="JOURNAL_ARTICLE">
<AU>Collins SL, Moore RA, McQuay HJ</AU>
<TI>The visual analogue pain intensity scale: what is moderate pain in millimetres?</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>72</VL>
<PG>95-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1998" NAME="Collins 1998" TYPE="JOURNAL_ARTICLE">
<AU>Collins SL, Edwards J, Moore A, McQuay HJ</AU>
<TI>Single dose dextropropoxyphene in postoperative pain: a quantitative systematic review</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1998</YR>
<VL>54</VL>
<PG>107-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-1999" MODIFIED="2008-05-28 15:21:21 +0100" MODIFIED_BY="Sheena Derry" NAME="Collins 1999" TYPE="COCHRANE_REVIEW">
<AU>Collins SL, Moore RA, McQuay HJ, Wiffen PJ, Edwards JE</AU>
<TI>Single dose oral ibuprofen and diclofenac for postoperative pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>4</NO>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-05-28 15:21:21 +0100" MODIFIED_BY="Sheena Derry">
<IDENTIFIER MODIFIED="2008-05-28 15:21:21 +0100" MODIFIED_BY="Sheena Derry" TYPE="DOI" VALUE="10.1002/14651858.CD001548"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cook-1995" NAME="Cook 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cook RJ, Sackett DL</AU>
<TI>The number needed to treat: a clinically useful measure of treatment effect</TI>
<SO>British Medical Journal</SO>
<YR>1995</YR>
<VL>310</VL>
<PG>452-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-1999" NAME="Edwards 1999" TYPE="JOURNAL_ARTICLE">
<AU>Edwards JE, McQuay HJ, Moore RA, Collins SL</AU>
<TI>Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>6</NO>
<PG>427-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hardman-1996" NAME="Hardman 1996" TYPE="BOOK">
<AU>Hardman JG, Gilman AG, Limbird LE</AU>
<SO>Goodman &amp; Gilman's 'The Pharmacological Basis of Therapeutics'</SO>
<YR>1996</YR>
<PG>617-57</PG>
<EN>Ninth</EN>
<PB>McGraw Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996a" NAME="Jadad 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Carroll D, Moore A, McQuay HJ</AU>
<TI>Developing a database of published reports of randomised clinical trials in pain research</TI>
<SO>Pain</SO>
<YR>1996</YR>
<VL>66</VL>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996b" NAME="Jadad 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lasagna-1962" NAME="Lasagna 1962" TYPE="JOURNAL_ARTICLE">
<AU>Lasagna L</AU>
<TI>The psychophysics of clinical pain</TI>
<SO>Lancet</SO>
<YR>1962</YR>
<VL>2</VL>
<PG>572-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-1998" NAME="McQuay 1998" TYPE="BOOK">
<AU>McQuay HJ, Moore RA</AU>
<SO>An evidence-based resource for pain relief</SO>
<YR>1998</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1996" NAME="Moore 1996" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics</TI>
<SO>Pain</SO>
<YR>1996</YR>
<VL>66</VL>
<NO>2-3</NO>
<PG>229-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997a" NAME="Moore 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics. Verification from independent data</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<NO>1-2</NO>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997b" NAME="Moore 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Moore A, Moore O, McQuay H, Gavaghan D</AU>
<TI>Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: Use of pain intensity and visual analogue scales</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<NO>3</NO>
<PG>311-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997c" NAME="Moore 1997c" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, Collins SL, Caroll D, McQuay HJ</AU>
<TI>Paracetamol with and without codeine in acute pain: a quantitative systematic review</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>70</VL>
<PG>193-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-1997d" NAME="Moore 1997d" TYPE="JOURNAL_ARTICLE">
<AU>Moore RA, McQuay HJ</AU>
<TI>Single-patient data meta-analysis of 3453 postoperative patients: Oral tramadol versus placebo, codeine and combination analgesics</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>69</VL>
<NO>3</NO>
<PG>287-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morris-1995" NAME="Morris 1995" TYPE="BOOK_SECTION">
<AU>Morris JA, Gardner MJ</AU>
<TI>Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates</TI>
<SO>Statistics with confidence - confidence intervals and statistical guidelines</SO>
<YR>1995</YR>
<PG>50-63</PG>
<ED>Gardner MJ, Altman DG</ED>
<PB>British Medical Journal</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PACT-2006" NAME="PACT 2006" TYPE="OTHER">
<AU>Anonymous</AU>
<TI>Prescription Cost Analysis, England 2006</TI>
<SO>ISBN: 1-84636-035-6</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Dolci-1994">
<CHAR_METHODS>
<P>RCT, double blind, single oral dose, parallel groups. Assessed by observer in hospital at 0, 1, 1.5, 2 hours. Self assessed at home at 3, 4 hours. Medication taken when pain of moderate to severe intensity</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Dental surgery<BR/>N = 336<BR/>Age &gt; 18<BR/>298/336 patients data analysed. <BR/>38 excluded: 15 lost to follow up, 6 violated protocol, 3 experienced adverse event, 14 did not have moderate or severe pain</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dosing regimen:<BR/>Placebo, n = 76</P>
<P>Piroxicam, n = 76</P>
<P>Paracetamol, n = 72</P>
<P>Piroxicam beta cyclodextrin, n = 74<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcome measures:<BR/>Standard PI (4 point scale)</P>
<P>Standard PR (5 point scale)</P>
<P>Standard global rating (5 point scale)</P>
<P>Analgesic outcome results:<BR/>Mean TOTPAR at 4 hours:<BR/>Piroxicam = 11.14</P>
<P>Placebo = 5.41<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Remedication:<BR/>If patients remedicated, PR reset to 0 and PI to 3 for analysis</P>
<P>Quality score: 4</P>
<P>Adverse effects: <BR/>Placebo: 8 patients recorded 12 adverse events, causing 1 withdrawal</P>
<P>Piroxicam: 7 patients reported 7 adverse events, none withdrew.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sunshine-1988a">
<CHAR_METHODS>
<P>RCT, double blind, single oral dose, parallel groups. Assessed by observer in hospital at 0, 1, 2, 3, 4, 5, 6 hours. Medication taken when pain of moderate to severe intensity</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>General and gynaecological surgery</P>
<P>N = 151</P>
<P>Adults<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dosing regimen: Piroxicam, n = 50</P>
<P>Placebo, n = 48<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcome measures:<BR/>Standard PI (4 point scale)</P>
<P>Standard PR (5 point scale)</P>
<P>Analgesic outcomes:<BR/>SPID at 6 hours:<BR/>Piroxicam = 7.58</P>
<P>Placebo = 4.58</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Remedication:<BR/>If patients remedicated PR reset to 0 and PI to baseline for analysis</P>
<P>Quality score: 3</P>
<P>Adverse effects:<BR/>Placebo: 25 patients reported 41 adverse events, leading to 2 withdrawals</P>
<P>Piroxicam: 5 patients reported 7 adverse events, no withdrawals.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sunshine-1988b">
<CHAR_METHODS>
<P>RCT, double blind, single oral dose, parallel groups. Assessed by observer at baseline and then hourly for 12 hours. Medication taken when pain of moderate to severe intensity</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>General and gynaecological surgery</P>
<P>N = 61</P>
<P>Adults</P>
<P>Withdrawals:<BR/>Only 1 withdrawal - for protocol violation, none for adverse events.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dosing regimen:<BR/>Piroxicam 20 mg, n = 15</P>
<P>Piroxicam 40 mg, n = 15</P>
<P>Placebo, n = 16<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcome measures:<BR/>Standard PR (5 point scale)</P>
<P>Non-standard Visual analogue pain intensity scale (100 mm)</P>
<P>Analgesic outcomes:<BR/>TOTPAR at 6 hours:<BR/>Piroxicam 20 mg = 16.3</P>
<P>Piroxicam 40 mg = 16.6</P>
<P>Placebo = 7.3</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Remedication:<BR/>If patients remedicated, PR reset to 0 and PI to baseline for analysis</P>
<P>Quality score: 3</P>
<P>Adverse effects:<BR/>Placebo: 5 patients reported 7 adverse events.</P>
<P>Piroxicam 20 mg: 1 patient reported an adverse event.</P>
<P>Piroxicam 40 mg: 6 patients reported 6 adverse events.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Alpaslan-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Could not be obtained - not in British Library stock</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anderson-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Active control, no placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain intensity not assessed. Did not state which PI and PR scales were used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arvidsson-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain not moderate/severe or not measured<BR/>No single dose data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barbieri-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>No UK location</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bauduin-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bigler-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain not measured<BR/>Rectal administration<BR/>Not postop administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boeckstyns-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain not moderate/severe or not measured<BR/>Not oral piroxicam (rectal)<BR/>Other drugs used concurrently</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Breivik-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rescue analgesic given at 2 hrs, remedicators not excluded and pain assessments not reset.<BR/>Assessed piroxicam 10 mg</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bruno-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Noncomparative trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Celenza-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cruz-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Noncomparative trial<BR/>Not randomised, not double blind, no placebo<BR/>Nonstandard pain intensity scale</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-DeAndrade-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not assess analgesic properties of piroxicam</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Desjardins-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Desjardins-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dolci-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicated data - verified by author</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fasting-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frezza-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Could not be obtained - no UK location</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hilvano-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Noncomparative trial<BR/>Not randomised, not double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hutchison-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jain-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jonsson-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kakutani-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised, not double blind, no placebo<BR/>Piroxicam administered to all patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kavanagh-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Laska-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lysak-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marcucci-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Massart-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain not moderate/severe or not measured<BR/>Not postop assessment or administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meisel-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Melzsack-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain not moderate/severe or not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Michelacci-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain not moderate/severe or not measured<BR/>RCT-active control, no placebo<BR/>im piroxicam v oral PBCD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mogensen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mogensen-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moiniche-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain not moderate/severe or not measured<BR/>Not postop administration or assessment<BR/>Other drugs used concurrently</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moraes-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Noncomparative trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morrow-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment<BR/>im piroxicam preop</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Negm-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain not moderate/severe or not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Negm-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment<BR/>Not oral piroxicam (intracanal) )injection)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nelson-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nelson-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Hanlon-1996a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment<BR/>Baseline pain not moderate/severe or not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Hanlon-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment<BR/>Baseline pain not moderate/severe or not measured<BR/>im piroxicam preop</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Hanlon-1996c">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment Baseline pain not moderate/severe or not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ogunbode-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised - randomisation not stated<BR/>Baseline pain not moderate/severe or not measured<BR/>Not oral piroxicam (gel) in study 1</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohnishi-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain not moderate/severe or not measured<BR/>Placebo given to all patients - nonresponders then given piroxicam</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohnishi-1983a">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT - active control, no placebo<BR/>Included children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohnishi-1983b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment<BR/>Baseline pain not moderate/severe or not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olson-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Parsloe-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pase-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Patel-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postoperative pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Piironen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment<BR/>Baseline pain not moderate/severe or not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roelofse-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration - preoperative<BR/>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Selcuk-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fast dissolving formulation of piroxicam<BR/>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sencift-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fast dissolving formulation of piroxicam<BR/>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Serpell-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment<BR/>Baseline pain not moderate/severe or not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simone-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT - active control, no placebo<BR/>Not oral piroxicam (PBCD v iv tenoxicam)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Singson_x002d_Alday-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Noncomparative trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sunshine-1995a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sunshine-1995b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duplicate publication - see Sunshine 1998(1)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taboada-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop pain<BR/>Not oral piroxicam (gel)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teixeira-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop pain<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Utsunomiya-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vagnoni-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Lackner-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Baseline pain not moderate/severe or not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wakeling-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not postop administration or assessment<BR/>Baseline pain not moderate/severe or not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yagi-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not double blind<BR/>Baseline pain not moderate/severe or not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yoshimasu-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No extractable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Dolci-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sunshine-1988a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sunshine-1988b">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Piroxicam 20 mg versus placebo</NAME>
<DICH_OUTCOME CHI2="0.3899850156013178" CI_END="3.3019806290568843" CI_START="1.8237604795873066" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4539808018068885" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.5187745211622743" LOG_CI_START="0.26096780042658757" LOG_EFFECT_SIZE="0.38987116079443096" METHOD="MH" NO="1" P_CHI2="0.8228408875328601" P_Q="0.0" P_Z="3.0672886771685194E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="139" WEIGHT="99.99999999999999" Z="5.927955885613455">
<NAME>Participants with at least 50% pain relief</NAME>
<GROUP_LABEL_1>Piroxicam 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours piroxicam</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4787602202671213" CI_START="1.7679861820219769" EFFECT_SIZE="2.48" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="25" LOG_CI_END="0.541424495259913" LOG_CI_START="0.24747886639251943" LOG_EFFECT_SIZE="0.3944516808262163" ORDER="1469" O_E="0.0" SE="0.17266511745103671" STUDY_ID="STD-Dolci-1994" TOTAL_1="76" TOTAL_2="76" VAR="0.029813242784380307" WEIGHT="69.16996047430828"/>
<DICH_DATA CI_END="4.601182842618297" CI_START="0.9197280089581826" EFFECT_SIZE="2.057142857142857" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6628694916787077" LOG_CI_START="-0.03634058751672204" LOG_EFFECT_SIZE="0.3132644520809928" ORDER="1470" O_E="0.0" SE="0.41071946166510803" STUDY_ID="STD-Sunshine-1988a" TOTAL_1="50" TOTAL_2="48" VAR="0.16869047619047617" WEIGHT="19.76284584980237"/>
<DICH_DATA CI_END="7.207591382412414" CI_START="1.24868343979118" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.857790157355891" LOG_CI_START="0.0964523520834338" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1471" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Sunshine-1988b" TOTAL_1="15" TOTAL_2="15" VAR="0.2" WEIGHT="11.067193675889326"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Piroxicam 40 mg versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.207591382412414" CI_START="1.24868343979118" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.857790157355891" LOG_CI_START="0.0964523520834338" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.014026978507169184" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.456571758378515">
<NAME>Participants with at least 50% pain relief</NAME>
<GROUP_LABEL_1>Piroxicam</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours piroxicam</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.207591382412414" CI_START="1.24868343979118" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.857790157355891" LOG_CI_START="0.0964523520834338" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1472" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Sunshine-1988b" TOTAL_1="15" TOTAL_2="15" VAR="0.2" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-05-28 15:17:50 +0100" MODIFIED_BY="Sheena Derry">
<APPENDIX ID="APP-01" MODIFIED="2008-05-28 15:17:50 +0100" MODIFIED_BY="Sheena Derry" NO="1">
<TITLE MODIFIED="2008-05-28 15:17:48 +0100" MODIFIED_BY="Sheena Derry">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-28 15:17:50 +0100" MODIFIED_BY="Sheena Derry">
<P>
<B>Search strategy in MEDLINE</B>
<BR/>1. piroxicam [single term MeSH]<BR/>2. piroxicam<BR/>3. 1 OR 2<BR/>4. PAIN, POSTOPERATIVE [single term MeSH]<BR/>5. ((postoperative adj4 pain$) or (post-operative adj4 pain$) or post-operative-pain$ or (post$ NEAR pain$) or (postoperative adj4 analgesi$) or (post-perative adj4 analgesi$) or ("post-operative analgesi$")) [in title, abstract or keywords]<BR/>6. ((post-surgical adj4 pain$) or ("post surgical" adj4 pain$) or (post-surgery adj4 pain$)) [in title, abstract or keywords]<BR/>7. (("pain-relief after surg$") or ("pain following surg$") or ("pain control after")) [in title, abstract or keywords]<BR/>8. (("post surg$" or post-surg$) AND (pain$ or discomfort)) [in title, abstract or keywords]<BR/>9. ((pain$ adj4 "after surg$") or (pain$ adj4 "after operat$") or (pain$ adj4 "follow$ operat$") or (pain$ adj4 follow$ surg$")) [in title, abstract or keywords]<BR/>10. ((analgesi$ adj4 "after surg$") or (analgesi$ adj4 "after operat$") or (analgesi$ adj4 "follow$ operat$") or (analgesi$ adj4 follow$ surg$"))<BR/>11. OR/4-10<BR/>12. randomized controlled trial.pt.<BR/>13. controlled clinical trial.pt.<BR/>14. randomized controlled trials.sh.<BR/>15. random allocation.sh.<BR/>16. double-blind method.sh.<BR/>17. single blind method.sh.<BR/>18. clinical trial.pt.<BR/>19. exp clinical trials/<BR/>20. (clin$ adj25 trial$).ti,ab.<BR/>21. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>22. placebos.sh.<BR/>23. placebo$.ti,ab.<BR/>24. random$.ti,ab.<BR/>25. research design.sh.<BR/>26. OR/12-25<BR/>27. 3 AND 11 AND 26</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>